

Giuseppe Lanzarone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9849064/publications.pdf>

Version: 2024-02-01

7

papers

159

citations

1478505

6

h-index

1720034

7

g-index

7

all docs

7

docs citations

7

times ranked

242

citing authors

#	ARTICLE	IF	CITATIONS
1	Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cyto-reductive Therapy in Essential Thrombocythemia. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 939-949.	4.7	6
2	Frequency and risk factors for thrombosis in acute myeloid leukemia and high-risk myelodysplastic syndromes treated with intensive chemotherapy: a two centers observational study. <i>Annals of Hematology</i> , 2022, 101, 855-867.	1.8	19
3	The Prognostic Role of Cytogenetics Analysis in Philadelphia Negative Myeloproliferative Neoplasms. <i>Medicina (Lithuania)</i> , 2021, 57, 813.	2.0	2
4	A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. <i>Blood</i> , 2020, 136, 171-182.	1.4	65
5	The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib. <i>British Journal of Haematology</i> , 2018, 182, 701-704.	2.5	22
6	The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting. <i>Blood Cancer Journal</i> , 2018, 8, 49.	6.2	30
7	Can pegylated interferon improve the outcome of polycythemia vera patients?. <i>Journal of Hematology and Oncology</i> , 2017, 10, 15.	17.0	15